Enclara Pharmacia, Inc.

Enclara Pharmacia, Inc. provides specialized pharmacy solutions for hospice care, focusing on enhancing patient outcomes and optimizing medication management through innovative technology and dedicated pharmacist support. Founded in 1996 in Philadelphia, US, Enclara Pharmacia, Inc. specializes in pharmacy services for hospice providers.

The firm has undergone strategic changes to enhance its offerings and was recently acquired in December 2019 by Humana Inc for USD 707 mn, with the deal finalized in January 2020. The company is led by CEO Andy Horowitz, who has a background in healthcare management. Enclara Pharmacia specializes in providing comprehensive pharmacy solutions tailored for hospice providers, which includes an array of crucial services designed to enhance patient care while streamlining medication management. Their core offerings include a full-service pharmacy delivering medications directly to patients’ homes, a robust technology platform for efficient ordering and EMR integration, and 24/7 access to pharmacists trained specifically in hospice and palliative care.

Enclara’s services facilitate timely medication delivery and support clinical decision-making, primarily catering to hospice organizations across the United States to improve end-of-life care. Enclara Pharmacia generates revenue through a subscription model and direct service agreements with hospice providers, facilitating smooth medication management workflows. Contracts with hospice organizations provide pharmacy services in exchange for service fees, reflecting the comprehensive nature of their offerings, including the E3 Pro™ technology platform and the 24/7 pharmacist access feature. This integration of local pharmacy solutions and next-day medication delivery enhances the firm's value proposition, driving recurring revenue through ongoing service delivery.

Enclara Pharmacia is focused on expanding its product offerings and enhancing its technology platform to better support hospice care teams. The company aims to enter new geographic markets, specifically targeting underserved regions in the US by the end of 2025. The recent acquisition deal completed in January 2020 provides the necessary capital support to drive these initiatives, allowing Enclara to innovate and scale its operations effectively.